Physician profile
Subhashish Agarwal
NPI 1134173875
$377,636.71
in general payments reported to CMS, 2019-2025
24 companies · $8,506 in 2025
The $8,506 reported for 2025 was more than what 94% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61K · 2020: $19K · 2021: $76K · 2022: $127K · 2023: $37K · 2024: $50K · 2025: $8,506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $66K · Consulting Fee: $11K · Travel and Lodging: $8,999 · Food and Beverage: $8,094 · Honoraria: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $65,878.75 |
| Consulting Fee | $11,098.50 |
| Travel and Lodging | $8,999.46 |
| Food and Beverage | $8,094.33 |
| Honoraria | $1,200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $307,480.43 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $40,951.39 | 2021-2025 | Farxiga, Wainua, Brilinta |
| Novartis Pharmaceuticals Corporation | $13,671.73 | 2019-2025 | Leqvio |
| Pfizer INC. | $4,705.08 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $4,169.52 | 2022-2025 | |
| Bridgebio Pharma, INC. | $2,999.98 | 2025 | Attruby |
| Chiesi USA, INC. | $1,214.82 | 2020-2024 | Juxtapid |
| Novo Nordisk INC | $452.93 | 2023-2025 | Ozempic, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $402.09 | 2022-2024 | Camzyos, Eliquis |
| Amgen INC. | $334.16 | 2019-2024 | Repatha |
| Alnylam Pharmaceuticals INC. | $269.07 | 2024-2025 | Amvuttra, Onpattro |
| Esperion Therapeutics, INC. | $175.10 | 2024-2025 | Nexletol |
| Janssen Scientific Affairs, LLC | $153.73 | 2024 | Xarelto |
| Boston Scientific Corporation | $122.49 | 2019-2023 | Watchman Flx |
| Merck Sharp & Dohme LLC | $94.28 | 2022-2024 | Verquvo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.05 | 2019-2024 | Jardiance |
| Daiichi Sankyo INC. | $79.89 | 2023 | Injectafer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $59.61 | 2023-2024 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $50.39 | 2023-2024 | Opsumit, Uptravi |
| Heartflow, INC. | $49.01 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $43.47 | 2023-2024 | Inpefa |
| Sanofi-Aventis U.S. LLC | $33.21 | 2019 | |
| Cvrx, INC. | $21.71 | 2024 | Barostim Neo System |
| Scpharmaceuticals INC. | $18.57 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subhashish Agarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.